Decoy Therapeutics Inc.
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture pe… Read more
Decoy Therapeutics Inc. (DCOY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.388x
Based on the latest financial reports, Decoy Therapeutics Inc. (DCOY) has a cash flow conversion efficiency ratio of -0.388x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.65 Million) by net assets ($4.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Decoy Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Decoy Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Decoy Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Decoy Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DHTRF
PINK:DHTRF
|
-0.025x |
|
New Mountain Finance Corporation
NASDAQ:NMFC
|
0.018x |
|
DAIWA SEC GRP - Dusseldorf Stock Exchang
DU:DSE
|
N/A |
|
Trustpilot Group PLC
LSE:TRST
|
0.675x |
|
HELIX ENERGY SOLNS
MU:CTV
|
0.035x |
|
ASURE SOFTWARE (VTE1.SG)
STU:VTE1
|
0.007x |
|
TAKIX
NMFQS:TAKIX
|
N/A |
|
ENGI11F
SA:ENGI11F
|
N/A |
Annual Cash Flow Conversion Efficiency for Decoy Therapeutics Inc. (2014–2024)
The table below shows the annual cash flow conversion efficiency of Decoy Therapeutics Inc. from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.51 Million | $-4.53 Million | -2.994x | -23.21% |
| 2023-12-31 | $5.29 Million | $-12.85 Million | -2.430x | -43.39% |
| 2022-12-31 | $10.38 Million | $-17.60 Million | -1.694x | -543.23% |
| 2021-12-31 | $38.72 Million | $-10.20 Million | -0.263x | +43.39% |
| 2020-12-31 | $22.16 Million | $-10.31 Million | -0.465x | +57.48% |
| 2019-12-31 | $10.58 Million | $-11.58 Million | -1.094x | +56.95% |
| 2018-12-31 | $9.28 Million | $-23.60 Million | -2.542x | -166.91% |
| 2017-12-31 | $29.11 Million | $-27.72 Million | -0.952x | -76.27% |
| 2016-12-31 | $59.32 Million | $-32.05 Million | -0.540x | -140.12% |
| 2015-12-31 | $92.19 Million | $-20.75 Million | -0.225x | -121.23% |
| 2014-12-31 | $-6.54 Million | $-6.93 Million | 1.060x | -- |